Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 9:8:23-33.
doi: 10.2147/JHC.S286213. eCollection 2021.

The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma

Affiliations

The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma

Siming Li et al. J Hepatocell Carcinoma. .

Abstract

Background: Currently, there is still a lack of effective biomarkers for the recurrence monitoring and survival prognosis assessment of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP)-negative (≤20 ng/mL) after radical resection.

Methods: The clinicopathological data of 606 patients (303 in the AFP-negative group and 303 in the AFP-positive group) who underwent radical resection of HCC were analyzed retrospectively.

Results: The gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) of patients in the AFP-negative group was lower than that in the AFP-positive group (p <0.001). The GLR level of the early-recurrence group was higher than that of the non-early-recurrence group (p =0.003). GLR had fair accuracy in predicting the early-recurrence of HCC patients [c-index=0.654 (95% CI=0.606-0.702); AUC=0.681 (95% CI=0.625-0.733)]. Univariate analysis showed that patients with tumor size <5 cm, no microvascular invasion, single tumor, no metastasis, BCLC stage 0-A, no recurrence, and GLR ≤45.0 had longer disease-free survival (DFS) and overall survival (OS) among AFP-negative HCC patients. In addition, multivariate Cox proportional hazards regression analysis showed that tumor size <5 cm (p =0.003), no recurrence (p <0.001), and GLR <45.0 (p <0.001) were independent predictors of longer OS.

Conclusion: GLR may be a potential indicator for early recurrence monitoring and prognosis evaluation in HCC patients with AFP-negative after radical resection.

Keywords: AFP-negative; GLR; early-recurrence; hepatocellular carcinoma; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart showing the inclusion process of eligible patients in the study.
Figure 2
Figure 2
The role of GLR in the prediction and evaluation of early recurrence in different groups of HCC. (A) The scatter plot showed the difference in GLR level between the early-recurrence group and the non-early-recurrence group. (B) The ROC curve was performed to assess the role of GLR in predicting early recurrence of HCC.
Figure 3
Figure 3
The relationship of GLR level with recurrence rate and OS in AFP-negative HCC patients. Kaplan–Meier analysis revealed a significantly higher recurrence rate (A) and shorter OS (B) in AFP-negative HCC patients with GLR ≤45.0 than in those with GLR >45.0. The OS of AFP-negative patients was longer than that of AFP-positive patients (C). The OS of patients with GLR ≤45.0 was longer than that of patients with GLR >45.0 (D). The postoperative recurrence rate of AFP-negative patients was highest in the GLR >45.0 and TS >5 cm group, and lowest in the GLR ≤45.0 and TS ≤5 cm group (E), while the OS of patients was lowest in the GLR >45.0 and TS >5 cm group, and highest in the GLR ≤45.0 and TS ≤5 cm group (F).

Similar articles

Cited by

References

    1. Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492 - DOI - PubMed
    1. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9):djx030. doi:10.1093/jnci/djx030 - DOI - PMC - PubMed
    1. Yang S, Liu L, Yang S, et al. Preoperative serum alpha-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103(6):716–724. doi:10.1002/bjs.10093 - DOI - PubMed
    1. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524–532. doi:10.1111/j.1572-0241.2006.00443.x - DOI - PubMed

LinkOut - more resources